High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER
There are as many rare disease patients as there are diabetics, Cigna’s Steve Miller notes, arguing that exorbitant prices for each treatment could drive counterproductive categorical exclusions by payers.
You may also be interested in...
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.
US Health and Human Services Department revises approach to 340B administrative dispute resolution process and presiding panel in proposed rule.